Trials / Completed
CompletedNCT04209296
Chart Review of Patients Undergoing Ketamine Infusions
A Retrospective Chart Review of Patients Undergoing Ketamine Infusions at the Canadian Rapid Treatment Center of Excellence
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 891 (actual)
- Sponsor
- Brain and Cognition Discovery Foundation · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- —
Summary
The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from mental health conditions. The center focuses specifically on treating individuals suffering from major depression disorder, bipolar disorder, post-traumatic stress disorder and obsessive compulsive disorder as their primary diagnosis. Herein, this retrospective analysis aims to look at past data in order to further develop our understanding of ketamine in the use of psychiatry.
Conditions
- Major Depressive Disorder
- Bipolar Disorder
- Obsessive-Compulsive Disorder
- Post Traumatic Stress Disorder
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ketamine Hydrochloride | Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine. |
Timeline
- Start date
- 2019-12-03
- Primary completion
- 2023-09-14
- Completion
- 2023-09-14
- First posted
- 2019-12-24
- Last updated
- 2024-08-12
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04209296. Inclusion in this directory is not an endorsement.